GenSight Biologics S.A.
ISIN: FR0013183985 | Ticker: SIGHT | LEI: 549300NK4AB8OUEX1F54
Country: France
GenSight Biologics is is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases.
GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
2012
Served areaWorldwide
Headcount41
Headquarters74 Rue du Faubourg Saint-Antoine, 75012 Paris – France
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 47,361,000.00 | 56,648,000.00 | 25,941,000.00 |
| Noncurrent Assets | N/A | 3,602,000.00 | 3,285,000.00 | 2,994,000.00 |
| Property Plant And Equipment | N/A | 3,154,000.00 | 2,549,000.00 | 2,268,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 133,000.00 | 112,000.00 | 93,000.00 |
| Other Noncurrent Financial Assets | N/A | 315,000.00 | 624,000.00 | 632,000.00 |
| Current Assets | N/A | 43,759,000.00 | 53,363,000.00 | 22,947,000.00 |
| Current Trade Receivables | N/A | 52,000.00 | 754,000.00 | 0.00 |
| Cash and cash equivalents | 19,250,000.00 | 37,943,000.00 | 44,288,000.00 | 10,610,000.00 |
| Other Current Assets | N/A | 5,764,000.00 | 8,321,000.00 | 12,337,000.00 |
| Equity And Liabilities | N/A | 47,361,000.00 | 56,648,000.00 | 25,941,000.00 |
| Equity | 10,518,000.00 | 11,749,000.00 | 15,989,000.00 | -15,279,000.00 |
| Issued Capital | N/A | 1,022,000.00 | 1,158,000.00 | 1,158,000.00 |
| Retained Earnings Profit Loss For Reporting Period | N/A | N/A | -28,617,000.00 | -27,625,000.00 |
| Share Premium | N/A | 152,776,000.00 | 181,175,000.00 | 181,211,000.00 |
| Noncurrent Liabilities | N/A | 18,489,000.00 | 18,417,000.00 | 26,577,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 31,000.00 | 41,000.00 | 21,000.00 |
| Noncurrent Derivative Financial Liabilities | N/A | N/A | 0.00 | 3,447,000.00 |
| Other Noncurrent Liabilities | N/A | 2,294,000.00 | 6,281,000.00 | 7,678,000.00 |
| Noncurrent Portion Of Noncurrent Loans Received | N/A | 5,725,000.00 | 3,058,000.00 | 2,195,000.00 |
| Noncurrent Portion Of Noncurrent Bonds Issued | N/A | 3,715,000.00 | 2,586,000.00 | 7,051,000.00 |
| Current Liabilities | N/A | 17,123,000.00 | 22,242,000.00 | 14,642,000.00 |
| Current Provisions | N/A | 22,000.00 | 61,000.00 | 61,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 7,588,000.00 | 11,561,000.00 | 7,813,000.00 |
| Current Derivative Financial Liabilities | N/A | 3,845,000.00 | 2,536,000.00 | 0.00 |
| Other Current Liabilities | N/A | 2,703,000.00 | 2,675,000.00 | 4,339,000.00 |
| Current Loans Received And Current Portion Of Noncurrent Loans Received | N/A | 0.00 | 2,210,000.00 | 1,233,000.00 |
| Current Bonds Issued And Current Portion Of Noncurrent Bonds Issued | N/A | 2,405,000.00 | 2,465,000.00 | 302,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 4,394,000.00 | 5,276,000.00 | N/A |
| Revenue From Contracts With Customers | N/A | 5,276,000.00 | 2,582,000.00 |
| Other Income | 3,046,000.00 | 2,433,000.00 | 2,283,000.00 |
| Profit Loss From Operating Activities | -24,934,000.00 | -28,126,000.00 | -27,835,000.00 |
| Finance Income | 631,000.00 | 2,013,000.00 | 3,890,000.00 |
| Finance Costs | 9,711,000.00 | 2,502,000.00 | 3,674,000.00 |
| Income Tax Expense Continuing Operations | 2,000.00 | 2,000.00 | 5,000.00 |
| Profit (loss) | -34,015,000.00 | -28,617,000.00 | -27,625,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -34,015,000.00 | -28,617,000.00 | -27,625,000.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | N/A | 2,381,000.00 | -1,287,000.00 | -5,760,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | 344,000.00 | 2,398,000.00 | -2,152,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 926,000.00 | 928,000.00 | 1,061,000.00 |
| Adjustments For Provisions | N/A | 36,000.00 | 18,000.00 | -30,000.00 |
| Adjustments For Sharebased Payments | N/A | 3,455,000.00 | 4,834,000.00 | -3,364,000.00 |
| Other Adjustments For Noncash Items | N/A | 63,000.00 | 0.00 | 0.00 |
| Cash Flows From Used In Operating Activities | N/A | -15,044,000.00 | -17,139,000.00 | -33,753,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 6,000.00 | 32,000.00 | 252,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | N/A | 0.00 | 0.00 |
| Cash Flows From Used In Investing Activities | N/A | -376,000.00 | -16,000.00 | 172,000.00 |
| Proceeds From Issuing Shares | N/A | 23,134,000.00 | 28,094,000.00 | 1,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | N/A | N/A | 305,000.00 | 193,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 11,711,000.00 | 0.00 | 10,800,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 0.00 | 3,069,000.00 | 7,822,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 710,000.00 | 584,000.00 | 860,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 708,000.00 | 835,000.00 | 1,867,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 33,859,000.00 | 23,739,000.00 | 95,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 18,439,000.00 | 6,584,000.00 | -33,487,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 254,000.00 | -238,000.00 | -193,000.00 |
| Cash and cash equivalents | 19,250,000.00 | 37,943,000.00 | 44,288,000.00 | 10,610,000.00 |
Please note that some sums might not add up.
FR0013183985
LEI549300NK4AB8OUEX1F54
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.